Pricing Log in Create free account
Friday 6 November 2026 Export RCUS’s income statement to Excel — free account

Arcus Biosciences, Inc.

RCUS Healthcare Biotechnology

Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024.

Revenue
−65.4%
EPS
+21.3%
Free cash flow
+9.28%
Total debt
+4.08%

Quarter to September 2026, against a year earlier

18.29 0.60 +3.39%
Market cap
$2.5B
P/E
0.0×
Fwd P/E
−5.1×
Dividend yield
—
F-score
0/9
Altman Z
1.11
Beneish M
−2.42
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Arcus Biosciences, Inc. (RCUS) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Arcus Biosciences, Inc. (RCUS) trades at a EV/Sales of 17.5×. Over the past ten years it has ranged from −1.9× (April 2025) to 97.4× (May 2020); the current reading is higher than 72% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 6.8× 325.68%
FY2024 1.6× (77.08%)
FY2023 7.0× 38.61%
FY2022 5.0× (20.61%)
FY2021 6.3× (30.41%)
FY2020 9.1× (46.40%)
FY2019 17.0× 21.81%
FY2018 13.9× —
FY2017 0.0× —

Quarterly newest first

Period EV/Sales Change
Sep 2026 27.6× (1.65%)
Jun 2026 28.1× 233.70%
Mar 2026 8.4× 23.96%
Dec 2025 6.8× 127.82%
33 more quarters

Against its own ten years

Low −1.9× High 97.4×
Ten-year median 6.4×
Current reading's percentile 69

EV/Sales against peers

Company EV/Sales
PHVS Pharvaris N.V. compare n/m
MBX MBX Biosciences, Inc. compare n/m
ZLAB Zai Lab Limited Unsponsored ADR compare 4.7×
BEAM Beam Therapeutics Inc. compare 12.2×
RCUS Arcus Biosciences, Inc. 17.5×
RXRX Recursion Pharmaceuticals, Inc. compare 19.8×
XNCR Xencor, Inc. compare 21.6×
IDYA IDEAYA Biosciences, Inc. compare 63.7×
NAMS NewAmsterdam Pharma Company N.V. compare 66.6×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on RCUS